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CD40–CD40L costimulatory interactions are crucial for
allograft rejection, in that treatment with anti-CD40L
mAb markedly prolongs allograft survival in several
systems. Recent reports indicate that costimulatory
blockade results in deletion of graft-reactive cells,
which leads to allograft tolerance. To assess immunol-
ogic parameters that were influenced by inductive
CD40–CD40L blockade, cardiac allograft recipients
were treated with multiple doses of the anti-CD40L
mAb MR1, which was remarkably effective at pro-
longing allograft survival. Acute allograft rejection re-
sponses such as IL-2 producing helper cell priming,
Th1 priming, and alloantibody production were abro-
gated by anti-CD40L treatment. Interestingly, the
spleens of mice bearing long-term cardiac allografts
following inductive anti-CD40L treatment retained pre-
cursor donor alloantigen-reactive CTL, IL-2 producing
helper cells, and Th1 in numbers comparable to those
observed in naı̈ve mice. These mice retained the ability
to reject donor-strain skin allografts, but were in-
capable of rejecting the original cardiac allograft, or a
second donor-strain cardiac allograft. Further, differen-
tiated effector cells were incapable of mediating rejec-
tion following adoptive transfer into mice bearing long-
term allografts, suggesting that regulatory cell func-
tion, rather than effector cell deletion was responsible
for long-term graft acceptance. Collectively, these data
demonstrate that inductive CD40–CD40L blockade
does not result in the deletion of graft-reactive T cells,
but induces the maintenance of these cells in a quies-
cent precursor state. They further point to a tissue
specificity of this hyporesponsiveness, suggesting that
not all donor alloantigen-reactive cells are subject to
this regulation.
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Introduction
It has long been appreciated that two signals are required for
T-cell activation (1). The first signal results from the engage-
ment of the T-cell receptor (TCR) with the major histocompat-
ibility complex (MHC)–peptide complex on the antigen-pre-
senting cell (APC), and the second signal involves engage-
ment of costimulatory receptors on the T cell with their
respective ligands on the APC. Absence of the second signal
results in either T-cell anergy (1) or deletion of these cells
(2,3). The two best-characterized costimulatory pathways are
those involving CD28–CD80/86 and CD40–CD40 ligand
(CD40L) interactions. Both CD28–CD80/86 and CD40–
CD40L interactions are critical in T-cell priming, maturation,
and activation of the APC (4). Hence, the importance of the
CD28–CD80/86 and CD40–CD40L pathways in allograft re-
jection has been explored by a number of investigators [re-
viewed in (5,6)].
It is not fully understood how blockade of costimulatory mol-
ecules results in allograft acceptance. A number of mechan-
isms, including deletion and/or anergy of donor-reactive cells,
as well as the emergence of regulatory cells, have been pro-
posed (2,3). CD28 is constitutively expressed on naı̈ve T
cells, and engagement of the CD40–CD40L pathway is be-
lieved to be required for the up-regulation of CD80/86,
CD28’s cognate receptor(s) on the APC. Subsequent en-
gagement of the CD28–CD80/86 pathway results in the acti-
vation of the APC as well as the T cell (4). Thus, blockade of
the ‘upstream’ CD40–CD40L pathway is thought to prevent T
cells from receiving the requisite costimulatory signal through
CD28 (4), thus rendering the T cells anergic (1). However,
others have suggested that anti-CD40L treatment directly
transmits an immunomodulatory signal to the T cell, leading
to apoptosis of the cell, which cannot be reversed by CD28
stimulation (7). In addition, deletion of donor-reactive cells
resulting from costimulatory blockade cells has been pro-
posed as a necessary step in achieving transplantation toler-
ance (2,3). Indeed, recent reports indicate that apoptosis of
donor-reactive T cells following inductive CD40L blockade
and treatment with CTLA4-Ig is required for the establish-
ment of tolerance (8,9). Finally, anti-CD40L therapy has re-
cently been shown to induce regulatory cells that are capable
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of facilitating infectious tolerance (10). Hence, the current
study was aimed at further elucidating the mechanisms by
which inductive anti-CD40L therapy promotes long-term
allograft acceptance. This report demonstrates that inductive
CD40–CD40L blockade does not result in the deletion of do-
nor alloantigen-reactive cells. Rather, graft acceptance is as-
sociated with the maintenance of the cells in a quiescent,
precursor state. The potential induction and function of regu-
latory cells following anti-CD40L therapy is discussed.
Materials and Methods
Mice
Female C57BL/6 and BALB/c mice were obtained from Jackson Labora-
tories (Bar Harbor, ME, USA), and used between 6 and 12weeks of age.
Media
The culture medium used in these studies was DMEM supplemented with
0.27mM L-asparagine, 1.4mM L-arginine HCl, 14mM folic acid, 5¿10ª5 M
2-ME (all obtained from Sigma Chemical, St. Louis, MO, USA), 1.6mM L-
glutamine, 10mM HEPES buffer, 1.0mM sodium pyruvate, 100 units/mL
penicillin/streptomycin, 2% fetal calf serum (FCS) (all obtained from Life
Technologies, Grand Island, NY, USA).
Heterotopic cardiac transplantation
C57BL/6 (H-2b) mice were transplanted with intact BALB/c (H-2d) cardiac
allografts, as described (11). In this model, the donor heart is anastomosed
to the great vessels of the abdomen, is perfused with the recipient mouse’s
blood and resumes contraction. Transplant function is monitored by daily
abdominal palpation.
A group of mice that had accepted their abdominal cardiac allografts fol-
lowing inductive anti-CD40L treatment were transplanted with a second
BALB/c cardiac allograft in the cervical position, as described (12), with
slight modifications. Briefly, end-to-side anastomoses were performed be-
tween the donor heart’s aorta and pulmonary artery and the recipient’s
carotid artery and jugular vein, respectively. In this model, allograft function
was monitored visually for contraction.
Skin grafting
Skin (approximately 1cm2 in diameter) was prepared from the abdominal
region of either allogeneic BALB/c or syngeneic C57BL/6 donors. Skin was
excised from the recipients’ upper torso and the donor skin was then
placed over the incision and held in place with wound clips. Clips were
removed 3days post-skin transplantation, and skin grafts were monitored
daily. Skin grafts were considered rejected when the majority of the graft
tissue was shed.
Inductive anti-CD40L therapy
Anti-CD40L mAb (hybridoma MR1, kindly provided by Dr Randy Noelle,
Dartmouth College) was purified by Lygocyte Pharmaceuticals (Bozeman,
MT, USA). Biologic activity of anti-CD40L preparations was verified in
mixed lymphocyte cultures, where maximal inhibition of proliferation was
achieved at 100mg/mL. Allograft recipients were injected i.p. with 1mg of
anti-CD40L on days 0, 1, 2, 4, 6, 8, 10 (7mg total), or on days 0, 1, 2
(3mg total) after transplantation. Both MR1 regimens resulted in uniform
prolonged graft survival (.60days) and identical immune responsiveness.
Control allograft recipients were either given equivalent amounts of ham-
ster IgG (h-IgG, Accurate Chemicals, Westbury, NY, USA) or were left un-
treated.
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Adoptive transfer of differentiated effector cells into mice bearing
long-term cardiac allografts
Spleens were harvested 10days post transplantation from unmodified allo-
graft recipients that had acutely rejected their grafts. Spleens were pooled
and processed into single-cell suspensions, and 5¿107 splenocytes were
injected i.v. into mice bearing long-term (day 60) cardiac allografts. These
splenocytes were also injected into SCID allograft recipients as a positive
control for their ability to mediate graft rejection.
Histology
Fragments of cardiac allografts were fixed in 10% neutral formalin, embed-
ded in paraffin, sectioned at 5mM, and stained with hematoxylin and eosin
(H&E) for examination by light microscopy. Where indicated, sections were
processed for trichrome or elastin staining to detect collagen deposition
and neointimal development, respectively. Parameters assessed included
the intensity and composition of cellular infiltration into the grafts, myocyte
death, as determined by nuclear degradation and by loss of cross striation,
and inflammation of the coronary vessels.
Assessment of primed and precursor Th1 function
To monitor primed Th1 function, splenocytes (1¿106 cells/mL) isolated
from allograft recipients were stimulated with irradiated (5000R) donor
strain splenocytes (1¿106 cells/mL) for 72h, and the concentration of in-
terferon (IFN)g in the culture supernatant was measured by ELISA (see
below). This assay detects in vivo primed Th1, in that splenocytes from
naive, nontransplanted mice produce minimal or undetectable concen-
trations of IFNg under these conditions (13,14). To detect quiescent precur-
sor Th1, splenocytes were stimulated for 5days with irradiated donor strain
splenocytes (15). Resulting cell populations were harvested, washed, and
restimulated with irradiated donor cells for an additional 72h, and the con-
centration of IFNg in the culture supernatant was measured by ELISA.
IFNg ELISA
Experimental samples (100mL) were added to ELISA plate wells that were
coated with 5mg/mL rat anti-mouse IFNg capture antibody (PharMingen,
San Diego, CA, USA). Following a 1-h incubation at room temperature,
plates were washed with Tween-20 (0.05%) in PBS and incubated with
100mL of rat anti-mouse secondary biotinylated antibody (1mg/mL) at room
temperature for 45min. Plates were then washed, and 100mL of avidin-
peroxidase (Sigma Chemicals, St Louis, MO, USA) was added. Following
a 30-min incubation at room temperature, plates were developed with
ABTS (2,2ƒ-azino-bis-3ethylbenzthiazoline-6-sulfonic acid) substrate
(Sigma Chemicals, St Louis, MO, USA). After 20min, absorbance was de-
termined at 405nm by an EL 800 microplate reader (Bio-Tek Instruments,
Winooski, VT, USA). Sample cytokine concentrations were calculated from
a standard curve that was derived from 2-fold serial dilutions of murine
recombinant IFNg. Data are reported as the mean and SD of IFNg values
for 6–10 individual animals.
Limiting dilution analysis (LDA) of donor-reactive IL-2 producing
helper T lymphocytes (HTL)
Two related LDA techniques were employed that distinguish in vivo primed
IL-2 producing HTL, from quiescent precursor HTL. These assays have pre-
viously been described in detail (16). The LDA technique employed to de-
tect in vivo primed cells is based on the principle that IL-2 production by
primed HTL, but not quiescent precursor HTL, is resistant to irradiation (17).
Hence, responder cells were irradiated (2000R) prior to addition to the
LDA microcultures to quantify primed HTL. To detect precursor HTL, re-
sponder cells were not irradiated. Irradiated allogeneic splenocytes
(5000R) were then added as stimulator cells, the microcultures were over-
laid with the IL-2-dependent cell line CTLL-20 (1¿103/well), pulsed with
3H-thymidine, and harvested. 3H-thymidine incorporation was determined
by scintillation (BetaPlate, Wallac, Gaithersburg, MD, USA). Individual
microcultures were considered positive for IL-2 production if 3H-thymidine
Alloimmunity and Anti-CD40L Therapy
incorporation exceeded the mean plus 3SD of 3H-thymidine incorporation
in microcultures lacking responder cells.
Limiting dilution analysis of donor-reactive precursor cytotoxic T
lymphocyte (CTL)
LDA was employed to quantify donor-specific CTL, as described (18).
Briefly, dilutions of responder cells were plated in the presence of irradiated
(2000R) allogeneic stimulators cells in DMEM containing 20% EL-4
supernatant as a source of growth factors and 10% FCS. Following a 7-
day incubation, cytolytic activity was detected by a standard 51Cr release
assay utilizing Con A-stimulated (1mg/mL) donor strain splenocytes as tar-
get cells. Microcultures were considered cytolytic if the observed chro-
mium release exceeded the mean plus 3SD of the chromium release in
wells that contained target cells, stimulator cells, but no responder cells.
Limiting dilution analysis data analysis
Minimal estimates of HTL or CTL frequency were obtained according to
the Poisson distribution equation as the slope of a line relating the number
of responder cells per microwell (plotted on a linear x axis) and the percen-
tage of microwells that failed to produce IL-2 or to develop cytolytic activity,
respectively (plotted on a logarithmic y axis). The slope of this regression
line was generated by computer using chi-square minimization analysis,
as described (19). This analysis yields a minimal frequency estimate, 95%
confidence interval of the frequency estimate, and a chi-square estimate
probability.
Alloantibody determination
P815 cells (H-2d) were stained for flow cytometric analysis using diluted
(1 :50) sera obtained from cardiac allograft recipients as the primary anti-
body, followed by FITC-conjugated isotype specific anti-mouse IgM, IgG1,
or IgG2a secondary antibodies (The Binding Site, San Diego, CA, USA)
used at a 1 :50 dilution. Data are reported as the mean channel fluor-
escence determined on a Becton Dickinson FACSCaliber (San Jose, CA,
USA).
The enzyme-linked immunospot (ELISPOT) assay for IL-4 produc-
ing cells
The ELISPOT assay used to quantify alloantigen primed IL-4 producing
cells has been described (20). Capture and detection anti-IL-4 mAb were
obtained from Pharmingen. Polyvinylidene fluoride bottomed plates (Jade
Scientific, Canton, MI, USA) were coated overnight with capture anti-IL-4
mAb (11.B11, 2mg/mL), blocked for 90min with 1% BSA in PBS at R.T.,
and washed 3 times with PBS. Irradiated (5000R) donor splenocytes
(4¿105) were added to each well followed by 1¿106 recipient splenocyt-
es. Plates were incubated for 24h at 37 æC, washed 3 times with PBS, and
washed 4 times with PBS-Tween-20 (0.05%). Biotinylated detection anti-
IL-4 mAb (BZD6–24G2, 2mg/mL) was added to each well and incubated
overnight at 4 æC. Plates were washed 3 times with PBS-Tween-20, and
Table1: Impact of inductive anti-CD40L therapy on allograft survival
Recipient Survival in days Mean∫SD
Unmodified 7 (nΩ4), 8 (nΩ2) 7.25∫0.46*
h-IgG treated 7 (nΩ2), 8 (nΩ4) 7.70∫0.51*
Anti-CD40L treated 60π (nΩ60) .60**
C57BL/6 mice were transplanted with BALB/c cardiac allografts and
were either left untreated, or given control hamster IgG (h-IgG) or
anti-CD40L mAb on days 0, 1 and 2 post transplantation. Trans-
plant function was evaluated by daily palpation. A ‘π’ indicates that
allografts were functioning at the time of harvest.
* Not significantly different.
** p ,0.05 compared to unmodified and h-IgG treated recipients.
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horse-radish peroxidase conjugated Strepavidin (1 :2000 dilution, DAKO
Corp., Carpinteria, CA, USA) was added for 90min at R.T. Plates were
washed 4 times with PBS, developed with AEC, washed with H20, and
air-dried. Spots were enumerated using an ImmunoSpot Series 1 ELISPOT
Analyzer (Cellular Technology Ltd, Cleveland, OH, USA).
Statistical analyses
P-values were obtained for graft survival using the log-rank comparison,
generated by Kaplan-Meier survival curves. P-values for other data were
determined using one-way ANOVA analysis with Tukey-Kramer post-test.
All statistical analysis was performed using GraphPad Software (San Diego,
CA, USA).
Results
Inductive anti-CD40L therapy markedly prolongs
allograft survival
Cardiac allograft survival was monitored in unmodified recipi-
ents, recipients given inductive, multiple dose anti-CD40L
therapy, or control hamster IgG (h-IgG) antibodies (Table1).
The mean survival time for unmodified allograft recipients
was 7.25days, which was comparable to graft survival in re-
cipients treated with h-IgG. In contrast, multiple-dose induc-
tive anti-CD40L treatment resulted in uniform graft survival
of greater than 60days. Histological analysis of allograft re-
jection on day 7 in unmodified recipients revealed an intense
mononuclear cell infiltrate, many dead and degenerating
myocytes, inflamed arteries, and scattered areas of hemor-
rhage (Figure 1A). Allografts obtained from h-IgG-treated re-
cipients on day 7 exhibited a similar histological picture (data
not shown). In contrast, functioning allografts obtained from
anti-CD40L-treated recipients on day 7 post transplantation
contained a very mild, diffuse mononuclear cell infiltrate, vi-
able myocytes and uninvolved arteries (Figure 1B).
Inductive anti-CD40L treatment inhibits priming of
IL-2 producing HTL
In vivo priming of IL-2 producing HTL has previously been
reported to be associated with acute allograft rejection in this
model (21). Hence, we utilized LDA to monitor the impact of
anti-CD40L therapy on priming of donor-specific IL-2 pro-
ducing HTL (16). In vivo primed IL-2 producing HTL were
readily detected in unmodified and h-IgG-treated allograft re-
cipients on day 7 post transplantation, but were not detect-
able in recipients treated with inductive anti-CD40L therapy
(Table2). As anticipated, primed HTL were not detectable in
naı̈ve, nontransplanted mice. Donor-specific precursor IL-2
producing HTL frequencies were also determined by LDA, as
described (16). Precursor HTL frequencies were similar in all
groups (Table2), indicating that anti-CD40L therapy pre-
vented HTL priming, but did not result in the deletion of do-
nor-reactive HTL during this early post-transplant period.
In vivo priming of IFNg producing Th1
In this model, in vivo sensitization of IFNg-producing Th1 has
also been reported to be associated with acute allograft re-
jection (14,15). Hence, splenocytes from allograft recipients
were cultured in vitro in the presence of irradiated donor-
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Figure1: Anti-CD40L therapy prevents mononuclear cell in-
filtration and cardiac allograft damage. C57BL/6 mice were
transplanted with BALB/c cardiac allografts and were either left un-
treated (Panel A) or given anti-CD40L therapy (Panel B). On day
7 post transplantation, allografts were processed for H&E staining.
Unmodified rejection (Panel A, 200X) was characterized by an in-
tense mononuclear cell infiltrate, inflamed arteries, scattered areas
of hemorrhage (white arrows), and dead and degenerating myo-
cytes (black arrows). In contrast, functioning allografts harvested
from anti-CD40L treated recipients (Panel B, 200¿) contained a
very mild diffuse mononuclear cell infiltrate, myocytes remained vi-
able, and arteries were unremarkable. Photomicrographs are repre-
sentative of at least 6 individual transplants per group.
Table2:Anti-CD40L therapy inhibits donor-specific IL-2 producing HTL priming during acute rejection
Recipient treatment Primed HTL (95% C.I.) Precursor HTL (95% C.I.)
No transplant ,1/189900 1/8886 (1/6188–1/15752)
Unmodified 1/10157 (1/6982–1/18628) 1/7044 (1/4935–1/12296)
h-IgG treated 1/8162 (1/5727–1/14199) 1/11367 (1/7736–1/21422)
Anti-CD40L treated ,1/189900 1/8441 1/5929–1/14677)
C57BL/6 mice were transplanted with BALB/c allografts and were either left untreated, or given control hamster IgG (h-IgG) or anti-CD40L
mAb on days 0, 1 and 2 post transplantation. On day 7 post transplantation, recipient splenocytes were harvested and processed for use
as responder cells in LDA to quantify primed and precursor IL-2 producing HTL (see Methods and Materials). Naı̈ve C57BL/6 obtained from
nontransplanted mice served as negative controls for HTL priming. Data are presented as the frequency of primed and precursor IL-2
producing HTL and the 95% confidence interval (95% C.I.) of the frequency estimate. Data are representative of three separate experiments,
consisting of 3 mice per experimental group. Frequencies with overlapping 95% confidence intervals are not considered statistically different.
Limit of detection for the LDAΩ1/189900.
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Table3:Anti-CD40L therapy inhibits in vivo priming of IFNg produc-
ing Th1






C57BL/6 mice were transplanted with BALB/c allografts and were
either left untreated, or given control hamster IgG (h-IgG) or anti-
CD40L mAb on days 0, 1 and 2 post transplantation. On day 7 post
transplantation, recipient splenocytes were harvested and pro-
cessed for use as responder cells in mixed lymphocyte cultures
stimulated with irradiated BALB/c splenocytes. Naı̈ve C57BL/6
splenocytes obtained from nontransplanted mice served as nega-
tive controls for primed Th1 function. Supernatants were collected
at 72h, and IFNg concentrations were determined by ELISA. Data
are reported as the mean and SD of IFNg production of 6 individual
transplant recipients in the h-IgG-treated group and 10 individual
animals in the other experimental groups. *p,0.05 compared to
unmodified and h-IgG-treated recipients. Limit of detection for the
ELISA Ω 0.39ng/mL.
strain splenocytes for 72h, and culture supernatants were
assessed for IFNg production (Table3). This short-term stimu-
lation of cells with donor alloantigens results in the release of
IFNg from primed, but not quiescent precursor Th1 (13,14).
While splenocytes obtained from naı̈ve, nontransplanted
mice did not produce measurable IFNg in this assay, signifi-
cant IFNg production was observed by cells harvested from
unmodified and control h-IgG-treated allograft recipients. In
contrast, priming of IFNg-producing Th1 was not observed in
anti-CD40L-treated recipients.
Anti-CD40L therapy inhibits donor-reactive alloanti-
body production
Donor-specific alloantibody responses have also been as-
sociated with acute allograft rejection in this model (22).
Further, it is well established that CD40–CD40L interactions
are crucial for antibody isotype switching, in that cells from
animals deficient in either CD40 or CD40L fail to produce an
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isotype switch (23,24). Hence, donor-specific IgM, IgG1 and
IgG2a antibodies were monitored in the sera of allograft re-
cipients (Table4). While sera alloantibodies were readily de-
tectable in unmodified and h-IgG-treated allograft recipients,
they were not detected in anti-CD40L-treated recipients. It
should also be noted that CD4πT-cell independent IgM re-
sponse (22) was also prevented by anti-CD40L therapy
(Table4).
Inductive anti-CD40L therapy delays signs of chronic
rejection
While other immunosuppressive agents may prolong allograft
survival, chronic rejection generally develops in long-term
cardiac allografts (15,25,26), which may be observed by day
60 post transplant. Cardiac allografts that were harvested on
day 60 following inductive anti-CD40L therapy did not exhibit
overt signs of chronic rejection such as graft fibrosis and neo-
intimal development. Myocytes remained viable (Figure 2A),
and collagen deposition was minimal as assessed by tri-
chrome staining (Figure 2B). Further, neointimal development
was absent as assessed by elastin staining (Figure 2C), and
arteries remained patent. Hence, multiple-dose anti-CD40L
therapy appeared to delay the onset of chronic rejection rela-
tive to other immunosuppressive therapies that prolong graft
survival.
Precursor donor-reactive cells are maintained in re-
cipients bearing long-term cardiac allografts
Limiting dilution analysis was performed on splenocytes from
mice bearing long-term cardiac allografts to assess whether
graft acceptance was associated with a deletion of donor
alloantigen-reactive T cells (Table5). Precursor donor-reactive
IL-2 producing HTL and CTL frequencies were similar in mice
bearing long-term cardiac allografts to those observed in
naı̈ve, nontransplanted animals. To determine if precursor
Table4: Anti-CD40L therapy inhibits the production of donor-reac-
tive alloantibodies
Recipient treatment Mean channel fluorescence
IgM IgG1 IgG2a
No transplant 3.6 2.7 3.0
Unmodified 58.6 8.3 10.0
h-IgG treated 21.3 5.0 15.0
Anti-CD40L treated 4.4 2.4 2.6
C57BL/6 mice were transplanted with BALB/c allografts and were
either left untreated, or given control hamster IgG (h-IgG) or anti-
CD40L mAb on days 0, 1 and 2 post transplantation. Sera obtained
from naı̈ve, nontransplanted mice served as negative controls. H-2d
specific alloantibodies were assessed by incubating diluted (1 :50)
control sera or sera obtained from animals 7days post transplan-
tation with P815 (H-2d) target cells, followed by FITC-conjugated
isotype specific secondary antibodies (see Materials and Methods).
Donor-reactive alloantibodies were determined by FACS analysis
and reported as mean channel fluorescence. The mean channel
fluorescence of isotype control secondary antibodies was 2.8 (IgM),
3.1 (IgG1) and 2.9 (IgG2a). Data are representative of 3 separate
experiments consisting of 3 mice per experimental group.
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Figure2: Inductive anti-CD40L therapy delays the develop-
ment of chronic allograft rejection. C57BL/6 mice were trans-
planted with BALB/c cardiac allografts and given anti-CD40L ther-
apy. On day 60 post transplantation, functioning allografts were pro-
cessed for histologic analysis. H&E staining (Panel A, 200¿)
revealed viable myocytes and normal myocardial architecture. Tri-
chrome staining (Panel B, 200¿) revealed minimal collagen depo-
sition (blue staining) within the myocardium and the normal colla-
gen component of the arterial adventitia. Elastin staining (Panel C,
400¿) revealed near total absence of neointima development.
Photomicrographs are representative of at least 10 individual trans-
plants.
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Table5: Inductive anti-CD40L therapy does not result in the deletion of donor alloantigen-reactive T cells in mice bearing long-term cardiac
allografts
Recipient treatment Precursor HTL Precursor CTL Precursor Th1 IL-4 producing Th2
(95% C.I.) (95% C.I.) IFNg (ng/mL) ./106 cells)
No transplant 1/5709 1/1841 * 6.7∫1.28 ** 10.3∫8.5
(1/4083–1/9950) (1/1326–1/3011)
Long-term anti-CD40L 1/9045 1/1453 * 4.5∫0.25 ** 18.0∫5.6
(1/6185–1/16824) (1/1077–1/2222)
C57BL/6 mice were transplanted with BALB/c allografts and given inductive anti-CD40L therapy. On day 60 post transplantation, splenocytes
were harvested for use in donor-specific T-cell functional assays. Responses are compared to those mounted by splenocytes obtained from
naı̈ve, nontransplanted mice. The frequencies of precursor IL-2 producing helper cells and cytotoxic T cells were determined by LDA, and
the data are reported as the minimal frequency estimate and 95% confidence interval. Precursor Th1 function was assessed as described
in Materials and Methods, and the data are presented as the mean and SD of IFNg release. IL-4 producing cells were quantified by ELISPOT,
and the data are reported as the number of spots per 106 cells. Results are representative of at least 6 individual animals.
*, ** Not significantly different.
Th1 were deleted in mice bearing long-term cardiac allo-
grafts, splenocytes were stimulated for 5days with irradiated
donor splenocytes, washed, and restimulated with donor
antigens for an additional 72h, as described (15). In this pre-
cursor Th1 assay, IFNg release was comparable when splen-
ocytes were obtained from mice bearing long-term cardiac
allografts or from naı̈ve mice. Hence, donor-reactive precur-
sor HTL, CTL and Th1 responses in mice bearing long-term
allografts were similar to those observed in naı̈ve mice, indi-
cating that these cells had not been deleted. Since costimu-
latory blockade has previously been reported to induce do-
Figure3: Differentiated effector cells are incapable of medi-
ating rejection of long-term cardiac allografts. Unmodified
C57BL/6 mice were transplanted with BALB/c allografts. On day 10
post transplantation, recipient spleens were harvested, pooled and
processed into single-cell suspensions. 5¿107 splenocytes were
adoptively transferred i.v. into SCID allograft recipients 5days post
transplantation, or into mice treated with inductive anti-CD40L ther-
apy that were bearing functioning allografts on day 60. Transplant
function was monitored by daily palpation. *p ,0.05.
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nor-reactive Th2 (27), we employed an ELISPOT assay to
quantify IL-4 producing Th2 responses (Table5). We have
reproducibly used this assay to quantify IL-4 producing cells
under conditions that favor in vivo Th2 development (28).
However, IL-4 producing Th2 responses were similar in mice
bearing long-term cardiac allografts and naı̈ve animals, indi-
cating that inductive anti-CD40L treatment did not preferen-
tially induce donor alloantigen-reactive Th2 responses.
Figure4: Induction of cardiac, but not skin allograft accept-
ance by anti-CD40L therapy. C57BL/6 mice were transplanted
with BALB/c cardiac allografts and given anti-CD40L therapy. On
day 60 post transplantation, mice were grafted with BALB/c skin or
were transplanted with a second BALB/c cardiac allograft placed in
the cervical position. Skin allograft (nΩ11) and secondary cardiac
allograft (nΩ8) survival times are reported. All primary cardiac allo-
grafts continued to function normally for the duration of the experi-
ment. *p ,0.05 for skin allograft vs. secondary cardiac allograft
survival.
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Differentiated effector cells are incapable of mediating
graft rejection in mice bearing long-term cardiac allo-
grafts
Since donor alloantigen-reactive cells were maintained in a
quiescent state in mice bearing long-term allografts, we
asked whether fully differentiated effector cells could mediate
rejection of these grafts. To this end, splenocytes were ob-
tained from unmodified allograft recipients on day 10, after
they had rejected their allografts. These effector cells were
adoptively transferred into mice bearing long-term (day 60)
cardiac allografts, or into SCID allograft recipients (Figure 3).
While SCID recipients of these effector cells readily rejected
their allografts (mean graft survival Ω 10.1days), the vast ma-
jority of mice bearing long-term cardiac allografts retained
functioning grafts as long as 40days following the adoptive
transfer of effector cells. These observations are consistent
with the presence of regulatory cells that are capable of
silencing effector cell function.
Mice bearing long-term cardiac allografts reject donor
strain skin grafts, but not secondary cardiac grafts
To further characterize the state of allograft acceptance fol-
lowing inductive anti-CD40L therapy, mice bearing long-term
cardiac allografts were grafted with either donor-strain skin
allografts (Figure 4) or isografts (data not shown). Skin allo-
grafts, but not isografts, were uniformly rejected by day 13
post-skin grafting. However, the original cardiac allografts
continued to function in mice that had rejected the donor-
strain skin grafts. Histological analyses of these cardiac allo-
grafts revealed only minimal or no changes relative to the
long-term allografts depicted in Figure 2 (data not shown).
At least two possibilities could explain these observations: (i)
The original cardiac allograft had lost its immunogenicity with
time in the recipient, or (ii) a state of tissue-specific allograft
hyporesponsiveness had been established. To discriminate
between these possibilities, mice bearing long-term cardiac
allografts were transplanted with a second donor-strain car-
diac allograft in the cervical position (Figure 4). Interestingly,
7/8 of these mice failed to reject their second donor-strain
cardiac allograft, and all mice retained their original abdomi-
nal allograft. Histologic examination revealed that both the
primary abdominal and the secondary cervical cardiac allo-
grafts remained free of overt tissue damage (Figure 5). Col-
lectively, these results argue against the loss of allograft
immunogenicity as an explanation for long-term graft accept-
ance. Further, they suggest that a state of tissue-specific allo-
graft acceptance had been induced.
Discussion
Although several groups have reported that blockade of
CD40–CD40L interactions results in prolonged allograft sur-
vival (29–33), the mechanism by which this occurs has not
yet been fully defined. Hence, the focus of this study was to
provide further insight into the immunologic parameters that
are influenced by anti-CD40L therapy and that are associated
with long-term allograft acceptance. While several studies
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Figure5: Histology of primary and secondary cardiac allo-
grafts following inductive anti-CD40L therapy. C57BL/6 mice
were transplanted with BALB/c cardiac allografts and given anti-
CD40L therapy. On day 60 post transplantation, mice were trans-
planted with a second BALB/c cardiac allograft placed in the cervi-
cal position. Thirty days later, both the primary abdominal (Panel A)
and the secondary cervical (Panel B) cardiac allografts were har-
vested and processed for H&E staining. In both cases, allografts
exhibited normal myocardial architecture with viable myocytes, un-
involved arteries, and a mild diffuse mononuclear cell infiltrate
(400¿). Photomicrographs are representative of allografts obtained
from 7 individual transplant recipients.
have shown that anti-CD40L therapy is less effective when
used alone (29,30,33,34), we found that three 1-mg doses
of anti-CD40L mAb as a sole immunosuppressant resulted
in uniform long-term acceptance of cardiac allografts
(Table1). The enhanced protective activity of this higher-dose
anti-CD40L therapy used in our study is likely due to distinct
dosing regimens employed by these previous studies. The
increased dose of anti-CD40L did not result in noticeable
side-effects and appeared to dissipate from the circulation,
in that mice transplanted with allografts 28days following the
initiation of therapy acutely rejected their grafts (data not
shown). Nonetheless, our data demonstrate that long-term
allograft acceptance following inductive anti-CD40L therapy
may be achieved in the continued presence of donor allo-
antigen-reactive T cells (Table5). Hence, inductive anti-
CD40L therapy did not result in the deletion of donor-reactive
T cells, but allowed these cells to be maintained in numbers
similar to those found in naı̈ve mice.
Nathan et al.
The mechanism involved in maintaining donor-reactive T cells
in a quiescent state remains to be established. Waldmann
and colleagues (10) have recently demonstrated that induc-
tive anti-CD40L therapy promotes the development of cells
that are capable of mediating infectious tolerance when naı̈ve
precursor cells are adoptively transferred into to mice bearing
long-term skin allografts. Further, the current study revealed
that infusion of differentiated effector cells obtained from
mice that had rejected cardiac allografts were incapable of
rejecting long-term cardiac allografts following inductive anti-
CD40L therapy (Figure 3). Collectively, these data suggest
that anti-CD40L therapy induces regulatory cells that are
capable of preventing precursor as well as differentiated ef-
fector cells from mediating graft rejection. The finding that
mice bearing long-term cardiac allografts were capable of
rejecting donor-strain skin grafts, but not secondary cardiac
allografts (Figures 4 and 5) suggests that these putative regu-
latory cells may function in a tissue-specific manner. Indeed,
the nature of a primary allograft has been shown to dramati-
cally influence the fate of subsequent transplants (35). It
should be noted that cardiac allograft rejection is ac-
companied by the development of cardiac myosin-specific
effector cells (36). Furthermore, the presence of cardiac myo-
sin-reactive antibodies has been associated with an increase
in the frequency and severity of cardiac allograft rejection epi-
sodes in man (37). Similarly, Sachs and coworkers have re-
cently identified skin-specific antigens that are not expressed
in cardiac or hematopoietic tissue (38). Hence, skin-specific
effector cells may be induced by skin grafting that would not
be induced by a second cardiac graft. It is also conceivable
that the putative regulatory cells involved in anti-CD40L-in-
duced cardiac allograft acceptance may, in part, be cardiac
myosin specific. In addition to this notion of tissue-specific
regulatory cells, other possibilities should be considered. For
example, tissue-specific effector cells may be either deleted
or altered in function. These alterations in tissue-specific ef-
fector cells would not be detected by the assays employed
in our study. Further, the nature and content of APC in the
skin and heart may impact on tissue immunogenicity and
graft survival. Differences in skin and second cardiac allo-
grafts survival may also be influenced by the nature of the
lymphoid organs that drain these grafts.
Anti-CD40L therapy inhibited a number of immune par-
ameters that have been historically associated with acute
allograft rejection, including the production of both IgM and
IgG alloantibodies (Table4), and the priming of Th1 (Table3)
and IL-2 producing HTL (Table2). It should be noted that
lower-dose anti-CD40L therapy does not prevent intragraft
cytokine gene expression (29), suggesting that T-cell priming
may not be prevented by low-dose regimens. Several of
these observations suggest that immune responses that are
modified by anti-CD40L therapy may be distinct from re-
sponses that occur in mice that are deficient in CD40L
(CD40L –/–). For example, CD40L –/– mice are capable of
mounting IgM antibody responses (24). However, treatment
of cardiac allograft recipients with anti-CD40L mAb abro-
gated the production of IgM alloantibodies (Table4). It should
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be noted that prolonged renal allograft survival in nonhuman
primates treated with a humanized anti-CD40L mAb was as-
sociated with the delayed (30–60days) development of low
titer donor-reactive IgG, but not IgM antibodies (32). The
delayed production of these IgG antibodies had no impact on
transplant survival, and these antibodies were not deposited
in the allograft at detectable levels. In addition, CD40L –/–
mice have been shown to mount normal Th1 responses
when challenged with Histoplasma capsulatum (39). How-
ever, we found that anti-CD40L therapy prevented Th1 prim-
ing in response to cardiac transplantation (Table3). This ob-
servation may be related to anti-CD40L’s inhibitory effects on
IL-12 production (40). Finally, while CD40L –/– mice accept
cardiac allografts, the development of chronic graft arterio-
sclerosis is not prevented in these mice and is readily detect-
able by 8weeks post transplant (41). Allografts in CD40L –/–
recipients are also infiltrated by mononuclear cells and suffer
significant parenchymal cell damage (41). In our hands,
multiple dose anti-CD40L therapy abrogated mononuclear
cell infiltration, arteriosclerosis, and fibrosis of the graft (Fig-
ure 2), as assessed on day 60 post transplant. Others have
reported similar observations when anti-CD40L mAb is used
in conjunction with CTLA4-Ig (29). It should also be noted
that CD40L appears to be necessary for the progression of
nontransplant-associated atherosclerosis (42). Hence, clear
differences have been reported when CD40–CD40L interac-
tions are prevented by CD40L deficiency vs. treatment with
anti-CD40L mAb. Some of the above differences in
CD40L –/– mice and animals treated with anti-CD40L mAb
may be due in part to variables in distinct experimental sys-
tems. However, these discrepancies may also reflect the di-
rect immunomodulatory effects that anti-CD40L mAb has on
T cells (7).
It has been proposed that long-term allograft acceptance
may be facilitated by immune deviation towards Th2 dom-
inance (43). While long-term graft acceptance resulting from
blockade of the CD28-B7 pathway has been associated with
persistent Th2 responses (27), we were unable to detect ap-
preciable numbers of donor-reactive IL-4 producing cells in
mice given inductive anti-CD40L therapy (Table5). In keeping
with our observations, Larsen et al. (29) found that simul-
taneous blockade of the CD28-B7 and CD40-CD40L path-
ways inhibited both Th1 and Th2 gene expression. It should
be noted that a growing body of evidence indicates that the
Th2 cytokines IL-4 and IL-5 may contribute to allograft rejec-
tion (43). Hence, sparing or preferential induction of Th2 by
inductive anti-CD40L therapy could have a detrimental im-
pact on long-term allograft survival. However, these obser-
vations do not rule out a potential role for other Th2- or Th3-
associated cytokines, such as IL-10 and TGFb, in anti-CD40L
therapy-induced allograft acceptance. It is well established
that IL-10 (44) or TGFb (45) producing regulatory cells are
involved in the control of immune-mediated pathology in a
variety of disease states. In addition to the well-accepted role
of regulatory cells in regulating Th1 responses (44,45), IL-10
producing regulatory cells have recently be shown to inhibit
Th2 responses in vivo (46). Further, Orosz’s group has dem-
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onstrated that both IL-10 and TGFb contribute to the regula-
tion of DTH responses in mice bearing long-term cardiac allo-
grafts (47). The role of these anti-inflammatory cytokines in
anti-CD40L-induced graft acceptance remains to be estab-
lished.
In summary, our data indicate that deletion of donor allo-
antigen-reactive T cells, as assessed by a variety of in vitro
assays, is not necessary for long-term allograft acceptance
following inductive anti-CD40L therapy. Rather, our data are
in keeping with the recent report by Waldmann and co-
workers (10) that implicates regulatory cell development as a
critical feature in anti-CD40L-induced graft acceptance. It is
also possible that the cardiac allograft-specific tolerance re-
ported herein may be explained, in part, by a failure of anti-
CD40L-treated mice to develop cardiac myosin-specific ef-
fector cells (36) or by the induction of cardiac myosin-speci-
fic regulatory cells. These possibilities are currently being in-
vestigated.
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